Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome

  title={Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome},
  author={V K Kimiskidis and Ioanna Sakellari and Vaia Tsimourtou and V. Kapina and Sotirios Papagiannopoulos and Dimitrios Kazis and Nikolaos Vlaikidis and Achilles Anagnostopoulos and Athanasios Fassas},
  journal={Multiple Sclerosis},
  pages={278 - 283}
Malignant multiple sclerosis (MS) is a rare but clinically important subtype of MS characterized by the rapid development of significant disability in the early stages of the disease process. These patients are refractory to conventional immunomodulatory agents and the mainstay of their treatment is plasmapheresis or immunosuppression with mitoxantrone, cyclophosphamide, cladribine or, lately, bone marrow transplantation. We report on the case of a 17-year old patient with malignant MS who was… 

Figures from this paper

Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China

AHSCT is a feasible treatment for severe MS and its long-term efficacy is favorable, and the major early toxicity resulted in fever and late toxicity caused transplantation-related mortality due to severe pneumonia and varicella-zoster virus hepatitis, respectively.

Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis

In this review, it is described the method and the rationale of aHSCT, the more recently published studies that demonstrate its efficacy in selected multiple sclerosis cases, the problems related to safety and the transplant-related mortality risk of the procedure are described.

Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results

In this population with high baseline EDSS, a significant proportion of patients with advanced MS remained stable for as long as 7 years after transplant, suggesting HDIT/AHCT may be more effective in patients with less advanced relapsing/remitting MS.

Autologous hematopoietic stem cell transplantation in multiple sclerosis

Intense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS, and these results strongly support further phase III studies with primary clinical endpoints.

Hematopoietic stem cell transplantation in multiple sclerosis

A comprehensive study of the results obtained in several single‐center and multicenter studies of intensive immunosuppresion followed by hematopoietic stem cell transplantation, which revealed the capacity of autologous HSCT to suppress or markedly reduce gadolinium‐enhancing lesions.

Autologous hemopoietic stem cell transplantation for multiple sclerosis: Is it worthwile?

ASCT should be used early, during the inflammatory phase of the disease; very high-intensity pre-transplant conditioning regimens increase toxicity but do not seem to increase efficacy compared to intermediate-intensity regimens; the results are dramatic and life-saving in resistant, so-called “malignant” cases.

Stem Cell-based Therapies in Multiple Sclerosis

HSCT is not a therapy for the general population of MS patients; it is a powerful therapy with long-term benefits that need to be weighed against certain toxicity risks; and in critical situations, it may have a life-saving effect with a meaningful and long-lasting improvement of disability.

[Stem cell therapy in multiple sclerosis: a clinical update].

With upcoming new treatment compounds that to some extent act via lymphoablative properties, it remains essential to better select those patients who might profit most from stem cell therapy based on a justifiable benefit-to-risk ratio.

Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis.

Using high-intensity myeloablative chemotherapeutic agents, it is now possible to completely remove the peripheral immune system and replace it anew from autologous bone marrow-derived hematopoietic stem cells, purged of disease-causing MS cells.



Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis

The treatment with intense immune ablation followed by ASCT of three patients with malignant MS whose clinical course indicated a dramatically poor prognosis succeeded in halting the rapidly worsening course of disease.

Aggressive multiple sclerosis—is there a role for stem cell transplantation?

A recent clinical trial of 85 patients treated by HSCT revealed that more than 60% of patients may benefit from this procedure, and HSCT is thus a justified and feasible treatment in certain patient groups, although transplant-related mortality must be reduced.

Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study

Autologous HSCT appears feasible in MS; it does not aggravate disability and seems to offer a clinical benefit, however, these observations need confirmation and long-term outcomes will show if benefits counterbalance toxicity and cost.

Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring.

  • H. OpenshawB. Lund S. Forman
  • Medicine, Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2000

Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients

These data are the first to demonstrate that long-term suppression of inflammatory activity in MS patients who received HSCT does not depend on persisting lymphopenia and is associated with profound qualitative immunological changes that demonstrate a de novo regeneration of the T cell compartment.

Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database

HSCT was shown as a promising procedure to slow down progression in a subset of patients affected by severe, progressive MS; the safety and feasibility of the procedure can be significantly improved by appropriate patient selection and choice of transplant regimen.

Immunoablative therapy as a treatment aggressive multiple sclerosis.

Collection of hematopoietic stem cells from patients with autoimmune diseases

When corrected for patient weight and apheresis volume, progenitor cell yields tended to vary by underlying disease, prior medication history and mobilization regimen, and Trends in the approaches to, and results of, progensitor cell mobilization are suggested by this survey.

Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system

A randomized, sham‐controlled, crossover study has recently been completed at the Mayo Clinic, which addresses observations that suggest patients with acute, severe neurological deficits resulting from IIDDs, who fail to improve after high‐dose intravenous corticosteroids, may benefit from plasma exchange.

Acute/relapsing experimental autoimmune encephalomyelitis: Induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation

Results indicate that high doses of CY, followed by SBMT, induce long term antigen-specific tolerance presumably by a mechanism of clonal deletion or anergy.